Azilect (rasagiline tablets) is indicated for use as initial monotherapy in early Parkinson’s disease (PD) and as adjunct therapy to levodopa in moderate-to-advanced disease.
Teva has also launched its PD Exercise Kit to accompany Azilect. This kit includes information on the availability of once-daily Azilect, an online fitness tracker, and PD-specific exercise options.
Azilect was approved by the FDA in May, based on data from three multinational clinical studies. The studies, which included more than 1,500 patients, provided statistically significant evidence of efficacy, while also demonstrating good tolerability as both initial monotherapy in early disease and adjunct therapy in moderate-to-advanced disease.
“The launch of Azilect is exciting for physicians, their patients, and caregivers living with PD,” said Dr Warren Olanow, professor and chairman of the department of neurology at Mount Sinai School of Medicine. “Azilect’s availability and the PD Exercise Kit are new tools to help people living with PD better manage their disease.”